Format

Send to

Choose Destination
J Microbiol Immunol Infect. 2016 Feb;49(1):24-32. doi: 10.1016/j.jmii.2014.01.006. Epub 2014 Mar 21.

Immunization with antigenic extracts of Leishmania associated with Montanide ISA 763 adjuvant induces partial protection in BALB/c mice against Leishmania (Leishmania) amazonensis infection.

Author information

1
Instituto de Medicina y Biología Experimental de Cuyo (IMBECU), Centro Científico y Tecnológico de Mendoza, Consejo Nacional de Investigaciones Científicas y Técnicas, Mendoza, Argentina; Área de Parasitología, Facultad de Ciencias Médicas, Universidad Nacional de Cuyo, Mendoza, Argentina. Electronic address: diegocargnelutti@hotmail.com.
2
Área de Parasitología, Facultad de Ciencias Médicas, Universidad Nacional de Cuyo, Mendoza, Argentina.
3
Instituto de Medicina y Biología Experimental de Cuyo (IMBECU), Centro Científico y Tecnológico de Mendoza, Consejo Nacional de Investigaciones Científicas y Técnicas, Mendoza, Argentina.
4
Instituto de Patología Experimental (IPE), Centro Científico y Tecnológico de Salta, Consejo Nacional de Investigaciones Científicas y Técnicas, Salta, Argentina.

Abstract

BACKGROUND/PURPOSE:

A proper adjuvant has a relevant role in vaccine formulations to generate an effective immune response. In this study, total Leishmania antigen (TLA) formulated with Montanide ISA 763 or R848 as adjuvants were evaluated as a first generation Leishmania vaccine in a murine model.

METHODS:

Immunization protocols were tested in BALB/c mice with a subcutaneous prime/boost regimen with an interval of 3 weeks. Mice immunized with unadjuvanted TLA and phosphate-buffered saline (PBS) served as control groups. On Day 21 and Day 36 of the protocol, we evaluated the humoral immune response induced by each formulation. Fifteen days after the boost, the immunized mice were challenged with 1 × 10(5) promastigotes of Leishmania (Leishmania) amazonensis in the right footpad (RFP). The progress of the infection was followed for 10 weeks; at the end of this period, histopathological studies were performed in the RFP.

RESULTS:

Vaccines formulated with Montanide ISA 763 generated an increase in the production of immunoglobulin G (IgG; p < 0.05) compared with the control group. There were no statistically significant differences in IgG1 production between the study groups. However, immunization with TLA-Montanide ISA 763 resulted in an increase in IgG2a compared to the unadjuvanted control (p < 0.001). Also noteworthy was the fact that a significant reduction in swelling and histopathological damage of the RFP was recorded with the Montanide ISA 763 formulation.

CONCLUSION:

We conclude that the immunization of BALB/c mice with a vaccine formulated with TLA and Montanide ISA 763 generated a protective immune response against L. (L.) amazonensis, characterized by an intense production of IgG2a.

KEYWORDS:

BALB/c; Leishmania (Leishmania) amazonensis; Montanide ISA 763; R848; Vaccines

PMID:
24662018
DOI:
10.1016/j.jmii.2014.01.006
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center